Retatrutide

Home › Research › Retatrutide

View Retatrutide in the AxYn range →

Snapshot

Chemistry and make-up

Retatrutide is a synthetic 39-residue peptide engineered from a GIP peptide backbone and tuned so that a single molecule activates three receptors at once: GIP, GLP-1 and glucagon [A]. Three design features define it:

1. Non-coded amino acids for protease resistance. 2-aminoisobutyric acid (Aib) is placed at positions 2 and 20, with an α-methyl-leucine at position 13 and a C-terminal L-serinamide. These block dipeptidyl peptidase-4 (DPP-4) cleavage and slow enzymatic degradation, the same strategy used across this drug class [A][D]. 2. Fatty-acid acylation (lipidation) for albumin binding. Lys17 carries a C20 fatty diacid (eicosanedioic acid) side chain attached through a γGlu + AEEA/PEG hydrophilic linker. The fatty tail binds reversibly to serum albumin, which shields the peptide from renal filtration and enzymatic breakdown and stretches the circulating half-life out to a once-weekly profile [A][D]. Resolved (2026-07-30 cross-check): the acylation is a C20 diacid on Lys17, not the C18/Lys30 that some secondary sources cite. Confirmed from the PubChem CID 171934787 structure (SMILES and InChI both encode a C20 diacid) and patent-derived sequence, and consistent with the verified formula C221H342N46O68 (which itself encodes C20). Independently re-confirmed 2026-07-31 (tri-source, research MCP): Perplexity confirmed the core identity; Claude confirmed the structure with primary sources, returning the full residue tag `Y-{Aib2}-QGTFTSDYSI-{aMeLeu13}-LDK-{Lys17(AEEA-gGlu-C20 diacid)}-AQ-{Aib20}-AFIEYLLEG-GPSSGAPPPS-NH2` and citing the retatrutide process patent CN117903284A. The C18 figure belongs to semaglutide, not retatrutide. The CoA and mass spec remain what matter for QC. 3. Balanced-but-tuned potency. Relative to native hormones, retatrutide is reported as more potent at the human GIP receptor (by roughly 9-fold) and somewhat less potent at the glucagon and GLP-1 receptors, which is the deliberate balance behind its metabolic effect [A].

For QC, the salt/counterion (usually acetate) changes the molecular weight and the observed peptide content, so the CoA must state the salt form and give an expected vs observed mass by MS, not just “retatrutide”. Because this is a long, heavily modified peptide with acylation and multiple non-coded residues, synthesis-related impurities (deletion sequences, incomplete acylation, des-amido variants) are a real analytical concern.

What it is studied for (evidence)

• Mechanism: simultaneous agonism at GIP, GLP-1 and glucagon receptors. GLP-1 and GIP arms drive glucose-dependent insulin secretion and appetite/satiety effects; the glucagon arm is thought to raise energy expenditure and support hepatic fat handling, which is the rationale for the strong weight-loss and liver-fat signals [A].
• Established (good evidence, human): the Phase 2 obesity trial (NEJM 2023, Jastreboff et al.) was double-blind, randomised and placebo-controlled and reported mean body-weight reduction of about 24.2% at the 12 mg dose over 48 weeks versus ~2.1% for placebo (NEJM 389:514-526) [A]. A Phase 2a randomised trial in metabolic-dysfunction-associated steatotic liver disease (MASLD/MASH) reported large reductions in liver fat (PMC11271400) [A].
• Emerging (maturing fast): the Phase 3 TRIUMPH programme (obesity/weight management) plus the TRANSCEND (type 2 diabetes) and SYNERGY (MASLD/MASH) families, over 5,800+ participants. First Phase 3 readouts arrived late 2025 into 2026: TRIUMPH-4 (obesity with knee osteoarthritis) reported up to ~28.7% weight loss at 68 weeks, and TRIUMPH-1 reported up to ~28.3% at 80 weeks with the 12 mg dose (Lilly investor release, AJMC) [A/D — company-reported topline]. Further trials in type 2 diabetes, sleep apnoea, cardiovascular outcomes and liver disease are reading out through 2026.
• Marketing claims vs data: vendor and clinic pages present retatrutide as a finished weight-loss product with dosing schedules and “best of the class” framing. That is not its status. It is investigational, not approved anywhere, and long-term safety, cardiovascular outcome data and full Phase 3 publication are still in progress. Any listing that implies human use or gives dosing is both scientifically premature and a regulatory liability (see section 5).
• Human clinical status: investigational only. No marketing authorisation from FDA, EMA or MHRA. Phase 3 ongoing.

Handling, format and stability

Supplied lyophilised in a sealed vial. Reconstituted for research handling with a suitable aqueous diluent (no dosing or human-use guidance here). Store the lyophilised powder cold and protected from light; once reconstituted, the peptide is far less stable and is cold-chain dependent. As a large acylated peptide it is sensitive to repeated freeze-thaw, heat and light. Format is vial only in the research market (contrast the multi-dose pen/cartridge format used for the approved GLP-1 medicines, which is exactly what illicit sellers try to imitate).

Regulatory and trade status

• UK/EU RUO: research use only, not an approved medicine. This is the highest-risk item in the AxYn range for the “medicinal product by presentation” trap: under UK/EU medicines law a product can be treated as a medicine simply from how it is presented (named after a weight-loss drug, weight-loss claims, dosing, human-use framing), regardless of an RUO label. Retatrutide’s entire public reputation is “the strongest weight-loss drug”, so any listing language drifting toward that presentation invites classification as an unlicensed medicinal product. Keep listings and emails strictly RUO, no indications, no dosing, no weight-loss language.
• MHRA enforcement (direct red flag): in October 2025 the MHRA Criminal Enforcement Unit dismantled what it described as the UK’s first illicit weight-loss medicine manufacturing site and seized over 2,000 unlicensed retatrutide and tirzepatide pens ready for dispatch, its largest single seizure of trafficked weight-loss medicines on record. Enforcement in this class is active and rising, and retatrutide is named specifically (Pharmaceutical Technology, Osborne Clarke) [B].
• FDA: not approved. FDA has separately warned about unapproved GLP-1 drugs sold for weight loss (FDA) [B].
• WADA (sport): not an approved human medicine, so in a sport context it would fall under S0 (non-approved substances) and should be treated as prohibited. The broader GLP-1 class is on the WADA Monitoring Programme, not the Prohibited List: markers of semaglutide and tirzepatide are monitored in and out of competition from 1 January 2026, with no sanction attached [B].
• Customs / import: the GLP-1 class attracts the heaviest customs and regulatory scrutiny of any peptide category. Import and domestic distribution of retatrutide as a research chemical sits close to the line that MHRA is actively policing.

Sources

• [A] Jastreboff AM et al., “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial”, *NEJM* 2023;389:514-526 — https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
• [A] Retatrutide Phase 2a MASLD/MASH randomised trial — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11271400/
• [A] Review, “Triple Agonism Based Therapies for Obesity” (PMC12304053) — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304053/
• [A/D] Eli Lilly Phase 3 TRIUMPH-1 / TRIUMPH-4 topline (company-reported) — https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
• [A/D] TRIUMPH-1 detail, AJMC — https://www.ajmc.com/view/retatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial
• [B] MHRA seizure of retatrutide/tirzepatide pens, Oct 2025 (via Pharmaceutical Technology) — https://www.pharmaceutical-technology.com/news/mhra-illegal-glp-1ra-weight-loss-manufacturing-facility-shut-down/
• [B] Osborne Clarke, UK GLP-1 regulatory analysis — https://www.osborneclarke.com/insights/weighty-matters-glp-1s-and-uk-regulatory-diet-they-cannot-escape
• [B] FDA, concerns with unapproved GLP-1 drugs for weight loss — https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
• [B] WADA 2026 Prohibited List and Monitoring Programme (semaglutide/tirzepatide markers monitored from 1 Jan 2026; GLP-1s not prohibited) — https://www.wada-ama.org/en/prohibited-list
• [C] PubChem CID 171934787 / MedChemExpress (C221H342N46O68, MW 4731.33, CAS 2381089-83-2) — https://pubchem.ncbi.nlm.nih.gov/compound/171934787
• [D] Vendor/clinic profiles (Peptidepedia, PeptideEvidence, Peptide Protocol Wiki) — commercial; used only as leads for the acylation/structure detail, which is now resolved via the PubChem CID 171934787 structure ([B]), and they publish dosing, which we do not use.

Plain summary

Retatrutide is Eli Lilly’s investigational triple agonist (GIP + GLP-1 + glucagon), a 39-amino-acid lipidated peptide that produced the largest weight-loss numbers yet seen in trials (about 24% in Phase 2, ~28% in early Phase 3), but it is not approved anywhere and long-term safety data are still coming in. Commercially it is the single highest-risk item in the range: MHRA has already seized illegal retatrutide pens by name, and because its whole reputation is “the strongest weight-loss drug”, any listing that drifts into weight-loss or dosing language risks it being treated as an unlicensed medicine. Keep it strictly research-use-only, and insist on a full CoA with stated salt form and mass spec because there is no official reference standard for identity.

For laboratory and research use only (RUO). Not for human or veterinary use, not for consumption, and not a medicine. Information is a research summary, not medical advice, and contains no dosing guidance.

Sourcing this compound? See sourcing retatrutide in the UK for the checks worth making before buying from any supplier, and retatrutide price in the UK for what drives the cost.

Sourcing retatrutide in the UK, common questions

For laboratory research use only. Not for human or veterinary use, not for consumption, and not a medicine.

For laboratory research use only. Not for human or veterinary use, not for consumption, and not a medicine. This is a research summary, not medical advice, and contains no dosing guidance.